Login to Your Account

NuCana BioMed Gets $10.5M For ProTide Cancer Drugs

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, November 30, 2011
NuCana BioMed Ltd. raised £6.74 million (US$10.5 million) in a Series A round to advance a series of modified nucleoside analogues in cancer indications and has set its sights on becoming the Inhibitex Inc. or even the Pharmasset Inc. of the cancer world.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription